Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms
Metrics: PDF 2234 views | HTML 2700 views | ?
Jennifer J. Wheler1, Barbara A. Parker2, Jack J. Lee3, Johnique T. Atkins1, Filip Janku1, Apostolia M. Tsimberidou1, Ralph Zinner1, Vivek Subbiah1, Siqing Fu1, Richard Schwab2, Stacy Moulder4, Vicente Valero4, Maria Schwaederle5, Roman Yelensky6, Vincent A. Miller6, M Philip J. Stephens6, Funda Meric-Bernstam1, Razelle Kurzrock2
1 Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX
2 Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California at San Diego Moores Cancer Center,
3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
4 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
5 Center for Personalized Cancer Therapy, Moores Cancer Center, University of California San Diego, La Jolla, CA
6 Foundation Medicine, Cambridge MA
Jennifer Wheler, email:
Keywords: Genomics, Breast Cancer, PI3K, Clinical Trials
Received: February 7, 2014 Accepted: April 30, 2014 Published: May 2, 2014
Our analysis of the tumors of 57 women with metastatic breast cancer with next generation sequencing (NGS) demonstrates that each patient’s tumor is unique in its molecular fingerprint. We observed 216 somatic aberrations in 70 different genes, including 131 distinct aberrations. The most common gene alterations (in order of decreasing frequency) included: TP53, PIK3CA, CCND1, MYC, HER2 (ERBB2), MCL1, PTEN, FGFR1, GATA3, NF1, PIK3R1, BRCA2, EGFR, IRS2, CDH1, CDKN2A, FGF19, FGF3 and FGF4. Aberrations included mutations (46%), amplifications (45%), deletions (5%), splices (2%), truncations (1%), fusions (0.5%) and rearrangements (0.5%), with multiple distinct variants within the same gene. Many of these aberrations represent druggable targets, either through direct pathway inhibition or through an associated pathway (via ‘crosstalk’). The ‘molecular individuality’ of these tumors suggests that a customized strategy, using an “N-of-One” model of precision medicine, may represent an optimal approach for the treatment of patients with advanced tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.